The U.S. Food and Drug Administration (FDA) granted initial approval for Sitagliptin And Metformin Hydrochloride on December 2, 2025. This significant regulatory action, identified by Abbreviated New Drug Application (ANDA) 202388, marks the availability of a generic version of this important combination medication, with SANDOZ listed as the sponsor.

Background

This approval pertains to an Abbreviated New Drug Application (ANDA), which is the pathway for generic drug products to gain FDA clearance. An ANDA submission demonstrates that a proposed generic medicine is bioequivalent to, and has the same quality, strength, dosage form, route of administration, and intended use as, a previously FDA-approved brand-name drug. The FDA's rigorous review process for ANDAs ensures that generic medications are safe and effective, providing the same clinical benefits as their reference listed drug. The approval of Sitagliptin And Metformin Hydrochloride as a generic option expands the treatment landscape for patients.

What this means

The initial FDA approval of Sitagliptin And Metformin Hydrochloride, sponsored by SANDOZ, is poised to significantly impact patient access and healthcare costs. Generic approvals are a cornerstone of pharmaceutical competition, typically leading to substantial reductions in prescription drug prices. This increased affordability can enhance medication adherence and improve overall public health outcomes by making essential treatments more accessible to a broader patient population. For clinicians, the availability of a generic alternative offers greater flexibility in prescribing, allowing them to select cost-effective options without compromising on established efficacy and safety profiles. This development reinforces the FDA's commitment to fostering a competitive market for prescription drugs.

Source

This information is derived from an official announcement by the U.S. Food and Drug Administration (FDA) regarding the initial approval of Abbreviated New Drug Application (ANDA) 202388. The approval date was December 2, 2025, and further details can be verified on the accessdata.fda.gov website.